Skip to content

Development of an assay for detection of Circulating Endothelial Cell (CEC) and Circulating Endothelial Progenitor cell (CEP) by fluorescence-activated cell sorting (FACS) in cancer patients and healthy individuals.

Development of an assay for detection of Circulating Endothelial Cell (CEC) and Circulating Endothelial Progenitor cell (CEP) by fluorescence-activated cell sorting (FACS) in cancer patients and healthy individuals. - Development and validation of the CEC/CEP FACS assay

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON40594
Enrollment
70
Registered
2014-07-08
Start date
2015-03-31
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer malignancy

Interventions

None listed

Sponsors

Antoni van Leeuwenhoek Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: bInclusion criteria cancer patients: 1. Patients with histological or cytological proof of metastatic cancer. 2. Age * 18 years 3. Able and willing to give written informed consent 4. Able and willing to undergo blood sampling ;Inclusion criteria healthy volunteers: 1. Age * 18 years 2. Able and willing to give written informed consent 3. Able and willing to undergo blood sampling

Exclusion criteria

Exclusion criteria: Exclusion criteria cancer patients: 1. Patients with known alcoholism, drug addiction, psychotic disorders in the history and/or other reasons, for which they are not amenable for adequate follow up. 2. Uncontrolled infectious disease or known HIV-1 or HIV-2 type patients ;Exclusion criteria healthy volunteers: 1. Patients with known alcoholism, drug addiction, psychotic disorders in the history and/or other reasons, for which they are not amenable for adequate follow up. 2. Uncontrolled infectious disease or known HIV-1 or HIV-2 type patients 3. Prior history of malignancy, renal disease, cardiovascular disease.

Design outcomes

Primary

MeasureTime frame
A reproducible method for enumeration of CECs and CEPs in peripheral blood using FACS

Secondary

MeasureTime frame
Gain further insight in the origin of CECs and CEPs.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)